Evidence map›Paper›PMID 38117395›Full record

ReviewMolecular biotechnology2025

Unveiling the Psychedelic Journey: An Appraisal of Psilocybin as a Profound Antidepressant Therapy.

Fatima Iftikhar Shah, Somia Shehzadi, Fatima Akram, Ikram Ul Haq, Benish Javed, Sadeed Sabir, Yasha Kazim, Sehrish Ashfaq

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Fatima Iftikhar ShahThe University of Lahore, Lahore, Pakistan.
Somia ShehzadiThe University of Lahore, Lahore, Pakistan.
Fatima AkramInstitute of Industrial Biotechnology, Government College University, Lahore, 54000, Pakistan. fatima_iib@yahoo.com.ORCID http://orcid.org/0000-0001-8438-706X
Ikram Ul HaqInstitute of Industrial Biotechnology, Government College University, Lahore, 54000, Pakistan.
Benish JavedThe University of Lahore, Lahore, Pakistan.
Sadeed SabirThe University of Lahore, Lahore, Pakistan.
Yasha KazimThe University of Lahore, Lahore, Pakistan.
Sehrish AshfaqThe University of Lahore, Lahore, Pakistan.
University of Lahore · PKGovernment College University, Lahore · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression, a global health concern with significant implications for suicide rates, remains challenging to treat effectively with conventional pharmacological options. The existing pharmaceutical interventions for these illnesses need daily dosing, are accompanied by various adverse effects, and may exhibit limited efficacy in certain cases. However, hope emerges from an unlikely source-Psilocybin, a natural hallucinogen found in certain mushrooms. Recently, this enigmatic compound has garnered attention for its potential therapeutic benefits in addressing various mental health issues, including depression. Psilocybin alters mood, cognition, and perception by acting on a particular subtype of serotonin receptors in the brain. It's feasible that these shifts in consciousness will promote healing development, offering a novel approach to depression management. This comprehensive review explores psilocybin, derived from specific mushrooms, and its implications in the treatment of depression. The study examines new perspectives and therapeutic possibilities surrounding psilocybin, addressing existing gaps in academic literature. It delves into its biosynthesis, unique mechanisms of action, therapeutic applications, and anti-depressive effects. By uncovering the potential of this mind-altering substance, the review aims to advance psychiatric care, offering hope to those globally affected by depression.

Indexed as

Antidepressive AgentsDepressionHallucinogensPsilocybinAgaricalesAnimalsHumansAntidepressive AgentsHallucinogensPsilocybinDepressionDisorderHealthMushroomPsilocybin

Identifiers

PMID38117395
OpenAlexW4390005347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.